Skip to main content
Year archive

Evotec SE — 2022 filings

All 83 regulatory filings released by Evotec SE (EVT) in 2022, sourced directly from the official regulator.

83 Filings
2022 Period
2022 filings (83)
Filing Released Lang
Evotec achieves further progress in neuroscience collaboration with Bristol Myers Squibb
Legal Proceedings Report
2022-12-16 English
Declaration of Compliance with the German Corporate Governance Code for the year 2022
Governance Information
2022-12-01 English
Entsprechenserklärung zum Deutschen Corporate Governance Kodex für das Jahr 2022
Governance Information
2022-12-01 German
Declaration of Voting Results & Voting Rights Announcements 2022
Declaration of Voting Results & Voting Rights Announcements
2022-11-15 English
Präsentation Q3 2022
Investor Presentation FY 2022
2022-11-11 English
Evotec SE reports results for the first nine months 2022 and provides corporate update
Earnings Release 9M 2022
2022-11-09 English
Q3 statement / Q3 financial report 2022
Interim / Quarterly Report 9M 2022
2022-11-09 English
Evotec SE to announce results for the first nine months 2022 on 09 November 2022
Report Publication Announcement
2022-11-03 English
Evotec completes acquisition of Central Glass Germany
M&A Activity
2022-11-03 English
Evotec presents paradigm shift in biologics at Capital Markets Day
Regulatory Filings
2022-11-02 English
Evotec, CDP Venture Capital and Angelini Ventures launch translational partnership 'Extend' with leading Italian academic Institutions
Regulatory Filings
2022-10-28 English
Evotec enters partnership with Hannover Medical School to create molecular patient database in autoimmune diseases
Regulatory Filings
2022-10-25 English
Evotec launches PanOmics data analysis platform PanHunter at Bio-IT World
Regulatory Filings
2022-10-18 English
Evotec and TIAP expand LAB150 BRIDGE partnership to include Amgen
M&A Activity
2022-10-17 English
Declaration of Voting Results & Voting Rights Announcements 2022
Declaration of Voting Results & Voting Rights Announcements
2022-10-06 German
Company Presentation October 2022 (English)
Investor Presentation
2022-10-01 English
Just Evotec Biologics awarded contract from the U.S. Department of Defense under accelerated antibodies program
Regulatory Filings
2022-09-20 English
Evotec initiates ground-breaking for new biologics facility J.POD Toulouse, France (EU)
Regulatory Filings
2022-09-16 English
Evotec expands clinical and commercial drug substance manufacturing with acquisition of Central Glass Germany
Regulatory Filings
2022-08-25 English
Evotec SE reports results for the first half-year 2022 and provides corporate updates
Earnings Release H1 2022
2022-08-11 English
Präsentation H1 2022
Interim / Quarterly Report H2 2022
2022-08-11 English
Half-yearly financial report 2022
Interim / Quarterly Report H2 2022
2022-08-11 German
Just Evotec Biologics and Alpine Immune Sciences expand partnership for commercial process development of ALPN-303
Regulatory Filings
2022-08-10 English
Evotec SE reports first half-year 2022 results on 11 August 2022
Report Publication Announcement
2022-08-04 English
Evotec, Boehringer Ingelheim, and bioMerieux launch Aurobac, a joint venture to fight Antimicrobial Resistance
Regulatory Filings
2022-07-06 English
Evotec completes acquisition of Rigenerand
M&A Activity
2022-07-05 English
Company Presentation July 2022 (English)
Investor Presentation
2022-07-01 English
Declaration of Voting Results & Voting Rights Announcements 2022
Declaration of Voting Results & Voting Rights Announcements
2022-06-24 English
Evotec SE reports results of Annual General Meeting 2022
AGM Information
2022-06-22 English
Präsentation des Vorstands Hauptversammlung 2022
AGM Information
2022-06-22 German
DGAP-DD: Evotec SE english
Director's Dealing
2022-06-14 English
DGAP-DD: Evotec SE english
Director's Dealing
2022-06-14 English
Evotec enters a drug discovery collaboration with Janssen
M&A Activity
2022-06-14 English
Declaration of Voting Results & Voting Rights Announcements 2022
Declaration of Voting Results & Voting Rights Announcements
2022-06-08 English
Declaration of Voting Results & Voting Rights Announcements 2022
Declaration of Voting Results & Voting Rights Announcements
2022-06-07 English
Declaration of Voting Results & Voting Rights Announcements 2022
Declaration of Voting Results & Voting Rights Announcements
2022-06-03 English
Declaration of Voting Results & Voting Rights Announcements 2022
Declaration of Voting Results & Voting Rights Announcements
2022-06-01 English
Declaration of Voting Results & Voting Rights Announcements 2022
Declaration of Voting Results & Voting Rights Announcements
2022-06-01 English
Evotec adds cell therapy manufacturing facility with acquisition of Rigenerand
M&A Activity
2022-05-30 English
Evotec and Almirall enter into a multi-target alliance in medical dermatology
M&A Activity
2022-05-19 English
Evotec SE: Bekanntmachung der Einberufung zur Hauptversammlung am 22.06.2022 in Hamburg mit dem Ziel der europaweiten Verbreitung gema 121 AktG
AGM Information
2022-05-17 German
Evotec and Sernova announce exclusive strategic partnership for iPSC-based beta cell replacement therapy to advance a 'functional cure' for diabetes
M&A Activity
2022-05-17 English
Evotec SE reports results for the first quarter 2022 and provides corporate update
Earnings Release Q1 2022
2022-05-11 English
Präsentation Analystencall Ergebnisse Q1 2022
Investor Presentation Q1 2022
2022-05-11 English
Präsentation Q1 2022
Investor Presentation Q1 2022
2022-05-11 English
Q1 statement / Q1 financial report 2022
Interim / Quarterly Report Q1 2022
2022-05-11 English
Evotec and Bristol Myers Squibb extend and expand strategic partnership in protein degradation
Regulatory Filings
2022-05-10 English
Evotec and Bristol Myers Squibb extend and expand strategic partnership
M&A Activity
2022-05-10 English
Evotec SE to announce results for the first quarter 2022 on 11 May 2022
Report Publication Announcement
2022-05-04 English
Annual financial report 2021 (PDF)
Audit Report / Information FY 2021
2022-04-28 English
Annual financial report 2021 (PDF)
Audit Report / Information FY 2021
2022-04-28 English
Declaration of Voting Results & Voting Rights Announcements 2022
Declaration of Voting Results & Voting Rights Announcements
2022-04-19 English
Report Publication Announcement 2022
Report Publication Announcement
2022-04-12 English
Evotec SE fiscal year 2021 results: 'Setting the Pace' on the data-driven R&D Autobahn to Cures
Earnings Release FY 2021
2022-04-12 English
Präsentation FY 2021
Investor Presentation
2022-04-12 English
Evotec achieves programme designation in neuroscience collaboration with Bristol Myers Squibb
Regulatory Filings
2022-04-08 English
Evotec SE to announce results for fiscal year 2021 on 12 April 2022
Earnings Release FY 2021
2022-04-05 English
Evotec receives 3 m milestone payment for Bayer starting Phase II clinical development of DNP programme
Earnings Release FY 2022
2022-03-21 English
Evotec presents strategic roadmap towards precision medicine and confirms goals of Action Plan 2025 at Capital Markets Day
Investor Presentation
2022-03-02 English
Evotec expands molecular patient database with unique nephrotic syndrome cohort from the University of Bristol
Regulatory Filings
2022-03-01 English
Vergütungsbericht 2021 der Evotec SE
Remuneration Information
2022-03-01 German
Remuneration Report 2021 of Evotec SE
Remuneration Information
2022-03-01 English
Evotec SE: Bayer discontinues clinical development candidate eliapixant (BAY1817080), Evotec regains the rights to all P2X3 assets
Regulatory Filings
2022-02-04 English
Report Publication Announcement 2022
Report Publication Announcement
2022-01-31 English
Report Publication Announcement 2022
Report Publication Announcement
2022-01-31 English
Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Declaration of Voting Results & Voting Rights Announcements
2022-01-31 English
DGAP-DD: Evotec SE english
Director's Dealing
2022-01-25 English
DGAP-DD: Evotec SE english
Director's Dealing
2022-01-25 English
DGAP-DD: Evotec SE english
Director's Dealing
2022-01-25 English
DGAP-DD: Evotec SE english
Director's Dealing
2022-01-25 English
DGAP-DD: Evotec SE english
Director's Dealing
2022-01-25 English
DGAP-DD: Evotec SE english
Director's Dealing
2022-01-25 English
DGAP-DD: Evotec SE english
Director's Dealing
2022-01-25 English
DGAP-DD: Evotec SE english
Director's Dealing
2022-01-25 English
DGAP-DD: Evotec SE english
Director's Dealing
2022-01-25 English
DGAP-DD: Evotec SE english
Director's Dealing
2022-01-25 English
Evotec enters iPSC-based drug discovery partnership with Boehringer Ingelheim in ophthalmology
Regulatory Filings
2022-01-25 English
Correction of a release from 22/11/2021, 12:30 CET/CEST - Evotec SE: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Declaration of Voting Results & Voting Rights Announcements
2022-01-20 English
Evotec and Lilly enter into drug discovery collaboration in metabolic diseases
Regulatory Filings
2022-01-18 English
Declaration of Voting Results & Voting Rights Announcements 2022
Declaration of Voting Results & Voting Rights Announcements
2022-01-12 English
Evotec expands neuroscience collaboration with Bristol Myers Squibb to include new targeted protein degradation approach
Regulatory Filings
2022-01-11 English
DGAP-DD: Evotec SE english
Director's Dealing
2022-01-04 English
Evotec receives 7.5 m grant for development of COVID-19 therapeutic
Regulatory Filings
2022-01-03 English